The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction

Journal of Medical Genetics

Volumn 43, Issue 2, 2006, Pages 167-169

  Gonzalez P ^a   Garcia Castro, M ^a   Reguero, J R ^a   Batalla, A ^b   Ordonez A G ^c   Palop, R L ^d   Lozano, I ^a   Montes, M ^d   Alvarez V ^a   Coto, Eliecer ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c Hospital S Agustin   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MYOCYTE ENHANCER FACTOR 2; PROTEIN MYOCYTE ENHANCER FACTOR 2A; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ALLELES; CASE-CONTROL STUDIES; EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUCINE; MADS DOMAIN PROTEINS; MALE; MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; MYOGENIC REGULATORY FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROLINE;

EID: 32944473313     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2005.035071     Document Type: Article

References (13)

1. Akanaza H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 2003;92:1079-88.
2. Wang L, Fan C, Topol ES, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003;302:1578-81.
3. Firulli B, Miano JM, Bi W, Johnson W, Casscells W, Olson N, Schwarz JJ. Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells. Circ Res 1996;78:196-204.
4. Lusis AJ. Atherosclerosis. Nature 2000;407:233-40.
5. Cambien F. Coronary heart disease and polymorphisms in gene affecting lipid metabolism and inflammation. Curr Atheroscler Rep 2005;7:188-95.
6. Wang Q. Advances in the genetics basis of coronary artery disease. Curr Atheroscler Rep 2005;7:235-41.
7. Bhagavatula MR, Fan C, Shen GQ, Cassano J, Plow EF, Topol FJ, Wang Q. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet 2004;13:3181-8.
8. Weng L, Kavalar N, Ustaszewska A, Doelle H, Schackwitz W, Hebert S, Cohen J, McPherson R, Pennacchio LA. Lack of MEF2A mutations in coronary artery disease. J Clin Invest 2005;115:1016-20.
9. WHO MONICA Project. MONICA manual, revised edition. Geneva: WHO Cardiovascular Diseases Unit, 1990.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
11. Bachinski LL, Abchee A, Durand JB, Roberts R, Krahe R, Hobson GM. Polymorphic trinucleotide repeat in the MEF2A gene at 15q26 is not expanded in familial cardiomyopathies. Mol Cell Probes 1997;11:55-8.
12. Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA, Hill JA, Olson EN. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 2002;8:1303-9.
13. Morfini G, Pigino G, Brady ST. Polyglutamine expansion diseases: failing to deliver. Trends Mol Med 2005;11:64-70.